| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
|
| ln Vitro |
Dehydroglyasperin C (0.1–1 μM; 24 h) suppresses the expression of CDK–2, cyclin E, CDK4, and cyclin D1 and prevents the cell cycle from progressing from the G0/G1 to S phase as induced by PDGF. The phosphorylation of PDGF receptor-β, phospholipase C-γ1, AKT, and extracellular-regulated kinase 1/2 is significantly attenuated by dehydroglyasperin C, and DGC also inhibits cell migration and the dissociation of actin filaments by PDGF[1]. In human aortic smooth muscle cells (HASMC), dehydroglyasperin C (0.1–1 μM; 24 h) treatment significantly reduces PDGF-induced cell number and DNA synthesis in a dose-dependent manner without causing any cytotoxicity[1].
|
|---|---|
| ln Vivo |
Histological analysis of liver tissue from ICR mice treated with a combination of CCl4 and Dehydroglyasperin C (5 mg/kg; once) demonstrates decreased lipid droplet formation. Additionally, DGC showed a minor protective effect against CCl4 injection-induced centrilobular injury, possibly via CYP2E1 expression suppression[4].
|
| Cell Assay |
Cell Cycle Analysis[1]
Cell Types: Human aortic smooth muscle cells (HASMC) Tested Concentrations: 0.1 μM, 0.5 μM, 1 μM Incubation Duration: 24 hrs (hours) Experimental Results: Blocked the PDGF-induced progression through the G0/G1 to S phase of the cell cycle. Western Blot Analysis[1] Cell Types: Human aortic smooth muscle cells (HASMC) Tested Concentrations: 0.1 μM, 0.5 μM, 1 μM Incubation Duration: 24 hrs (hours) Experimental Results: Down-regulated the expression of CDK; 2, cyclin E, CDK4 and cyclin D1. |
| References |
|
| Molecular Formula |
C21H22O5
|
|---|---|
| Molecular Weight |
354.40
|
| Exact Mass |
354.14672380
|
| CAS # |
199331-35-6
|
| Appearance |
White to off-white solid
|
| SMILES |
CC(=CCC1=C(C2=C(C=C1O)OCC(=C2)C3=C(C=C(C=C3)O)O)OC)C
|
| InChi Key |
UACNRZUVCUEUPY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H22O5/c1-12(2)4-6-16-19(24)10-20-17(21(16)25-3)8-13(11-26-20)15-7-5-14(22)9-18(15)23/h4-5,7-10,22-24H,6,11H2,1-3H3
|
| Chemical Name |
4-[7-hydroxy-5-methoxy-6-(3-methylbut-2-enyl)-2H-chromen-3-yl]benzene-1,3-diol
|
| Synonyms |
Dehydroglyasperin C
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (282.17 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.05 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.05 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.05 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8217 mL | 14.1084 mL | 28.2167 mL | |
| 5 mM | 0.5643 mL | 2.8217 mL | 5.6433 mL | |
| 10 mM | 0.2822 mL | 1.4108 mL | 2.8217 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
